Table 1.
Primary and secondary outcomes in six Phase III randomized controlled trials of chemoradiotherapy interventions for ASCC
| Trial Authors, year of publication | Local treatment failure | Progression‐free survival | Disease‐free survival | Colostomy‐free survival | Colostomy | Acute toxicity | Overall survival | Cancer‐specific survival | Local/regional control |
|---|---|---|---|---|---|---|---|---|---|
| ACT I (1996) 5 | ✓1 | ♦ | ♦ | ♦ | |||||
| RTOG 87‐04 (1996) 7 | ✓2 | ♦ | ♦ | ♦ | ♦ | ♦ | ♦ | ||
| EORTC (1997) 6 | ✓3 | ♦ | ♦ | ♦ | |||||
| RTOG 98‐11 (2008) 4 | ✓ | ♦ | ♦ | ♦ | ♦ | ||||
| ACCORD‐03 (2012) 9 | ✓ | ♦ | ♦ | ♦ | |||||
| ACT II (2013) 8 | ✓4 | ✓ | ♦ | ✓ | ♦ | ♦ | ♦ |
✓Primary outcome; ♦ Secondary outcome; 1, clinically, at 6 weeks; 2, on biopsy, post‐irradiation; 3, clinically, at 6 weeks; 4, clinically, at 26 weeks; ASCC, anal squamous cell carcinoma.